Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.

Purpose: Survival of patients with metastatic sarcoma remains poor, and there is a pressing need for new therapies. Most sarcoma subtypes are not responsive to immune checkpoint inhibition alone. Lenvatinib, a multireceptor tyrosine kinase inhibitor targeting tumor vasculature, has an immunomodulatory activity that contributes to its antitumor effects.

Assessing the potential of n-alkyl amides and n-alkyl nitriles in the arid sedimentary strata of northwestern China as environmental indicators.

Recent advancements in the application of lipid biomarkers as paleoenvironmental indicators have provided invaluable insights into the dynamics of climatic variations, vegetative histories, and anthropogenic impacts. However, our current understanding of nitrogen-containing lipid biomarkers (NCLBs) in sedimentary deposits remains limited, notwithstanding their potential significance in global nitrogen cycling. To bridge this research gap, a comprehensive study was conducted to characterize the distribution patterns of n-alkyl amides (NAAs) and n-alkyl nitriles (NANs) in representative paleo-lake and loess sedimentary profiles from the arid region of northwestern China (NWC).

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.

Purpose: Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216 was designed to bind EWS::FLI1 proteins directly, disrupt protein-protein interactions, and inhibit transcription factor function. TK216 plus vincristine showed synergistic activity in preclinical tumor models.